Equinivesh Terminal — Compounder Valuation Calculator & Stock Strength Meter

Enter Company Name or NSE/BSE Ticker — Auto-Populates 100% of Valuation & 6-Pillar Fundamentals

NSE: TITAN Consumer Discretionary

Titan Company Ltd.

MCap: ₹3,12,450 Cr • Free Float Institutional

Live CMP

₹3,520

Google/Yahoo Sync

Quick Load:

Reported TTM P/E

86.4x

TTM EPS: ₹40.74

Normalized Core P/E

82.1x

Core EPS: ₹42.87

2-Yr Forward P/E (FY+2)

56.8x

5Y Med: 74.0x (-23%)

Growth-Adjusted PEG

3.73x

3Y EPS CAGR: 22.0%

5-Yr Avg ROCE / CFO

28.4% / 92%

High Capital Efficiency

Composite Quality & Valuation Engine

Stock Strength Meter & Institutional Verdict

Trap Risk Index: LOW (16%)

84 / 100

Compounder Strength Score

Institutional Verdict

FLAWLESS COMPOUNDER — HIGH CONVICTION BUY ZONE

Titan combines elite capital efficiency (28.4% ROCE) with strong cash conversion and a multi-decade formalization runway in jewelry & wearables. While trailing P/E appears optically rich, 2-year forward earnings growth compresses P/E below its 5-year median.

Reverse-DCF Implied Growth

18.4% / yr (10Y)

30% De-Rating Stress CAGR

+14.2% CAGR

Multi-Factor Fingerprint

6-Pillar Moat vs. Benchmark

Max 100 / Pillar

Target Company

Flawless Compounder (85+)

Value Investor Adjustments

P/E Normalization Breakdown

Read-Only Auto

Current Price (CMP ₹)

Reported TTM EPS (₹)

One-Time / Exceptional Adj (₹)

Non-Operating Income Adj (₹)

Cyclical Margin Adj (₹)

Projected EPS CAGR (%)

5-Yr Median Historical P/E

5-Yr Avg ROCE (%)

Reported TTM EPS: ₹40.74

Net Value-Investor Adjustments: +₹2.13

Normalized Core Operating EPS: ₹42.87

Current vs. 5-Yr Median P/E Premium: +10.9%

Time-Arbitrage Valuation

Forward P/E Compression Trajectory (TTM → FY+3)

Crosses Below 5Y Median in FY+1

Normalized TTM

82.1x

EPS ₹42.9

1-Yr Forward (FY+1)

67.3x

EPS ₹52.3

2-Yr Forward (FY+2)

55.2x

EPS ₹63.8

3-Yr Forward (FY+3)

45.2x

EPS ₹77.8

Downside Margin-of-Safety Simulation

5-Year Exit-Multiple De-Rating Stress Test

Tests whether projected 5-year earnings compounding overcomes severe P/E multiple contraction against a 15.0% Hurdle CAGR.

Starting Norm. P/E: 82.1x

Projected Year-5 EPS: ₹115.86

Stress Scenario	Multiple Contraction	Year-5 Exit P/E	Year-5 Projected EPS	Implied Year-5 Target Price	Expected 5-Yr Stock CAGR	Hurdle Verdict (15%+)

Interactive Institutional Due Diligence

6-Pillar Compounder vs. Overvalued Trap Checklist

Auto-scored from fetched company financials. Click any criterion below to toggle/override and observe live Stock Strength Meter recalculation.